The first officer or copilot is second in command to the captain and assists in flight preparations and the operation of the ...

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

Dyne Therapeutics (DYN) is stepping into a pivotal week, with investors laser focused on tomorrow’s topline readout from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial for DYNE-251 ...

Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The Alcorn State University Sounds of Dyn-O-Mite showed up and showed out at the 2025 Macy's Thanksgiving Day Parade.The band arrived in New York earlier this week. They had been posting updates of ...

It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind. 10 stocks we like better than Dyne ...

It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind. That research note was published on Sunday ...

The memecoin crashes through the critical $0.15 floor on exceptional volume, establishing new support near $0.138 as bears tighten control across major timeframes. Dogecoin’s chart suffered decisive ...

A peer is being acquired for a very high premium. The market is clearly thinking Dyne might be next on a potential buyer's shopping list. Both Dyne and Avidity are clinical-stage companies busy ...